Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Targeting Translation as a Druggable Opportunity in Breast Cancer
FY 2019-20
Summary
"In the cellular context, both normal and cancerous, information is largely relayed from DNA to mRNA to functional proteins via transcription and translation, respectively. This provides room for regulation at multiple levels of gene expression. Studies analyzing different mRNA and protein expression levels have determined that over 50% of all gene regulation occurs at the level of protein synthesis (translation). Additionally, it was found that dysregulated translation of certain mRNAs supports the cancer hallmarks. A key protein complex involved in translation initiation is eukaryotic initiation factor 4F (eIF4F). When dysfunctional, two signaling pathways that control eIF4F activity, the PI3K/mTOR and MAP kinase pathways, also play a role in the development of cancer. Current drugs target these pathways in an attempt to combat breast cancer; however, they are met with resistance over time due to the ability of cancer cells to shift to other pathways that bypass the drug's original target. To avoid resistance, it makes sense to directly target the common downstream endpoint of these signaling pathways which is the translation machinery, namely eIF4A, a subunit of eIF4F. CR-1-31b (CR) is a rocaglate compound that targets eIF4A and was most characterized by the Pelletier Lab. My project aims are to determine CR's effect on tumor growth and characterize its mRNA target(s) using genetically engineered mouse models of breast cancer and molecular biology techniques with the potential of creating synthetic derivatives pharmacokinetically optimized for clinical studies. This project should offer insight into the consequences and mechanisms of selectively inhibiting translation in breast cancer and hopefully highlight the advantages of rocaglates over currently marketed drugs."
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
428823
Name
Girgis Samer A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Translation as a Druggable Opportunity in Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cr-1-31b; Eif4a; Eif4f; Luminal B Breast Cancer Models (Gemms); Mmtv Polyomavirus Middle T; Polysome Profiling; Rna-Seq; Rocaglates; Translation Initiation; Tunel Assay
Abstract
"In the cellular context, both normal and cancerous, information is largely relayed from DNA to mRNA to functional proteins via transcription and translation, respectively. This provides room for regulation at multiple levels of gene expression. Studies analyzing different mRNA and protein expression levels have determined that over 50% of all gene regulation occurs at the level of protein synthesis (translation). Additionally, it was found that dysregulated translation of certain mRNAs supports the cancer hallmarks. A key protein complex involved in translation initiation is eukaryotic initiation factor 4F (eIF4F). When dysfunctional, two signaling pathways that control eIF4F activity, the PI3K/mTOR and MAP kinase pathways, also play a role in the development of cancer. Current drugs target these pathways in an attempt to combat breast cancer; however, they are met with resistance over time due to the ability of cancer cells to shift to other pathways that bypass the drug's original target. To avoid resistance, it makes sense to directly target the common downstream endpoint of these signaling pathways which is the translation machinery, namely eIF4A, a subunit of eIF4F. CR-1-31b (CR) is a rocaglate compound that targets eIF4A and was most characterized by the Pelletier Lab. My project aims are to determine CR's effect on tumor growth and characterize its mRNA target(s) using genetically engineered mouse models of breast cancer and molecular biology techniques with the potential of creating synthetic derivatives pharmacokinetically optimized for clinical studies. This project should offer insight into the consequences and mechanisms of selectively inhibiting translation in breast cancer and hopefully highlight the advantages of rocaglates over currently marketed drugs."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Girgis, Samer A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~